SELLAS Life Sciences

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell SLS and other ETFs, options, and stocks.

About SLS

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. 

CEO
Angelos M. Stergiou
CEOAngelos M. Stergiou
Employees
13
Employees13
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
2006
Founded2006
Employees
13
Employees13

SLS Key Statistics

Market cap
1.86B
Market cap1.86B
Price-Earnings ratio
-43.83
Price-Earnings ratio-43.83
Dividend yield
Dividend yield
Average volume
6.42M
Average volume6.42M
High today
$10.60
High today$10.60
Low today
$9.87
Low today$9.87
Open price
$10.37
Open price$10.37
Volume
5.04M
Volume5.04M
52 Week high
$15.88
52 Week high$15.88
52 Week low
$1.39
52 Week low$1.39

Stock Snapshot

With a market cap of 1.86B, SELLAS Life Sciences(SLS) trades at $10.04. The stock has a price-to-earnings ratio of -43.83.

As of 2026-08-01, SELLAS Life Sciences(SLS) stock has fluctuated between $9.87 and $10.60. The current price stands at $10.04, placing the stock +1.7% above today's low and -5.3% off the high.

SELLAS Life Sciences(SLS) shares are trading with a volume of 5.04M, against a daily average of 6.42M.

In the last year, SELLAS Life Sciences(SLS) shares hit a 52-week high of $15.88 and a 52-week low of $1.39.

In the last year, SELLAS Life Sciences(SLS) shares hit a 52-week high of $15.88 and a 52-week low of $1.39.

SLS News

TipRanks 1d
Cboe data shows mixed options sentiment in Sellas Life Sciences with shares down 3.3%

Cboe data shows mixed options sentiment in Sellas Life Sciences (SLS), with shares down 34c near $9.95. Options volume relatively light with 25k contracts trade...

Simply Wall St 2d
SELLAS Life Sciences Group Nears REGAL Readout As Valuation Questions Return

SELLAS Life Sciences Group (SLS) is back in focus as investors watch for the final analysis of its Phase 3 REGAL trial in acute myeloid leukemia, with the pivot...

SELLAS Life Sciences Group Nears REGAL Readout As Valuation Questions Return
Simply Wall St 4d
Is SELLAS Using AI To Reshape Its Precision Oncology Story Or Just Its Pitch?

Earlier in 2026, SELLAS Life Sciences Group’s CEO Angelos Stergiou underscored how AI and precision medicine could speed drug development and refine patient sel...

Is SELLAS Using AI To Reshape Its Precision Oncology Story Or Just Its Pitch?

More SLS News

TipRanks 5d
SELLAS Life Sciences Faces Adverse Arbitration Ruling

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

People also own

Based on the portfolios of people who own SLS. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.